

Provided by:



Movement Disorder Neurology Case Conference 2025-2026

Movement Disorder Neurology Case Conference 2025-2026 - 2/18/2026

February 18, 2026

5:00 PM - 6:30 PM

Penn Neurological Institute

Target Audience

This program has been designed for NEUROLOGY, NEUROLOGY WITH SPECIAL QUALIFICATION IN CHILD NEUROLOGY

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Describe unusual movement disorders
- 2 Discuss how to generate an appropriate differential diagnosis for patients with unusual movement disorders
- 3 Describe how to initiate adequate treatment for patients with unusual movement disorders

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.50 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for 1.50 contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.50 Category 1 credits for completing this activity.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

None

For more information, please contact
irene skirsky, Jen negron
(215) 829-8407, (215) 829-6708

irene.skirsky@uphs.upenn.edu, Jennifer.Negron@uphs.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

| Name of individual | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s) |
|--------------------------------|---------------------------------|---|
| Andres Deik Acosta Madiedo, MD | Other Planning Committee Member | Grant or research support-Teva Pharmaceuticals (Relationship has ended) Grant or research support-Lundbeck, LLC Royalties or Patent Beneficiary-Elsevier Key (Relationship has ended) Royalties or Patent Beneficiary-UpToDate Independent Contractor (included contracted research)-PeerView CME Grant or research support-Amylyx therapeutics (Relationship has ended) Grant or research support-Ono Pharmaceuticals Grant or research support-Asklepios Pharmaceuticals Consulting Fee-Amneal Therapeutics (Relationship has ended) Advisor-Manifold Bio Advisor-SPARKNS Consulting Fee-AbbVie, Inc. (Relationship has ended) Consulting Fee-Supernus (Relationship has ended) Grant or research support-Cerevel Therapeutics Grant or research support-Eli Lilly - 01/01/2026 |
| Sara Hughes, MSN, BSN | Co-Director | Nothing to disclose - 08/27/2025 |
| Andrew Siderowf, MD | Other Planning Committee Member | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Acadia (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Alerity Membership on Advisory Committees or Review Panels, Board Membership, etc.-AskBio (Relationship |

| | | |
|-----------------------|---------------------------------|--|
| | | has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Boehringer-Ingelheim (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Capsida (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Eli Lilly Consulting Fee-GE Healthcare (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Inhibikase Membership on Advisory Committees or Review Panels, Board Membership, etc.-Mitsubishi (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Wave Therapeutics - 03/02/2025 |
| Meredith Spindler, MD | Other Planning Committee Member | Grant or research support-Abbott/St. Jude (Relationship has ended) Grant or research support-Biohaven Pharmaceuticals Consulting Fee-Boston Scientific Corporation Grant or research support-UCB Grant or research support-Bial Grant or research support-Scion (Relationship has ended) Grant or research support-AbbVie, Inc. Grant or research support-Takeda Pharmaceuticals (Relationship has ended) Grant or research support-Praxis (Relationship has ended) Grant or research support-Supernus Advisor-Medtronic (Relationship has ended) Consulting Fee-Health and Wellness Partners, LLC (Relationship has ended) Royalties or Patent Beneficiary-Wolters Kluwer Consulting Fee-Putnam (Relationship has ended) - 07/07/2025 |
| Megan E Super, MD | Faculty | Nothing to disclose - 07/01/2025 |
| Pavan Vaswani, MD | Co-Director | Other: Travel support-Medtronic (Relationship has ended) - 07/07/2025 |

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected